I should have posted this a while ago but became side tracked with my Food Free Trunk or Treat events. I still feel it is pertinent although a bit late; the level of sarcasm is strong with this one…
As we know, Mylan has agreed to pay $465 Million as part of a Department of Justice Settlement for wrongly classifying EpiPen as a generic product. The generic classification allowed the company to pay substantially less in Medicare/Medicaid rebates: “Drugmakers are required by law to pay rebates for sales to patients insured by Medicaid, which is funded jointly by states and the federal government. By classifying EpiPen as a generic, Mylan paid a smaller rebate of 13%, or about $163 million, when it should have been paying a 23% or higher rebate for brand-name drugs, Mr. Slavitt wrote” as noted in the WSJ. It’s too bad the average American consumer isn’t privy to those lucrative rebates–but I digress.
Senator Amy Klobuchar (D.-Minn.) described the mis-classification as an “outrage.” And yes, we should be outraged…but not solely at Mylan.
